Cited 0 times in
A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이민구 | - |
dc.contributor.author | 윤지훈 | - |
dc.date.accessioned | 2021-12-28T17:25:50Z | - |
dc.date.available | 2021-12-28T17:25:50Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1744-6872 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187096 | - |
dc.description.abstract | Isoniazid is a therapeutic agent for the treatment of latent tuberculosis infection. Genetic variants in the N-acetyltransferase 2 (NAT2) are associated with the safety and pharmacokinetics of isoniazid. The study aimed to evaluate the safety and pharmacokinetics of a NAT2 genotype-guided regimen of isoniazid monotherapy. A randomized, open-label, parallel-group and multiple-dosing study was performed in healthy subjects. The subjects received isoniazid for 29 days. The NAT2 slow acetylators (NAT2*5/*5, -*5/*6, -*5/*7, -*6/*6, -*6/*7, -*7/*7) randomly received standard dose (300 mg, standard-treatment group) or reduced dose (200 mg, PGx-treatment group) of isoniazid. Also, all the NAT2 rapid acetylators (NAT2*4/*4) received isoniazid 300 mg (reference group). The safety and pharmacokinetics were evaluated during the study. The PGx-treatment group showed a more stable serum liver enzyme profile and a lower incidence of adverse drug reactions (ADRs) than the standard-treatment group. The emergence rates of ADRs were 12.5, 60 and 33.3% in the reference, standard-treatment and PGx-treatment groups, respectively. The PGx-treatment group showed higher plasma isoniazid concentrations than the reference group, although the PGx-treatment group received a reduced dose of isoniazid. Our results showed that a NAT2 genotype-guided regimen may reduce ADRs during isoniazid monotherapy without concern over insufficient drug exposure. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Lippincott Williams & Wilkins | - |
dc.relation.isPartOf | PHARMACOGENETICS AND GENOMICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antitubercular Agents / administration & dosage | - |
dc.subject.MESH | Antitubercular Agents / adverse effects | - |
dc.subject.MESH | Arylamine N-Acetyltransferase / genetics* | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Genotype | - |
dc.subject.MESH | Healthy Volunteers | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Isoniazid / administration & dosage* | - |
dc.subject.MESH | Isoniazid / adverse effects | - |
dc.subject.MESH | Latent Tuberculosis / drug therapy* | - |
dc.subject.MESH | Latent Tuberculosis / genetics* | - |
dc.subject.MESH | Latent Tuberculosis / microbiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pilot Projects | - |
dc.title | A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pharmacology (약리학교실) | - |
dc.contributor.googleauthor | Hyounggyoon Yoo | - |
dc.contributor.googleauthor | Sang Chun Ji | - |
dc.contributor.googleauthor | Joo-Youn Cho | - |
dc.contributor.googleauthor | Sang-Heon Kim | - |
dc.contributor.googleauthor | Jihoon G Yoon | - |
dc.contributor.googleauthor | Min Goo Lee | - |
dc.contributor.googleauthor | Kyung-Sang Yu | - |
dc.contributor.googleauthor | In-Jin Jang | - |
dc.contributor.googleauthor | Jaeseong Oh | - |
dc.identifier.doi | 10.1097/FPC.0000000000000423 | - |
dc.contributor.localId | A02781 | - |
dc.relation.journalcode | J02506 | - |
dc.identifier.eissn | 1744-6880 | - |
dc.identifier.pmid | 33165168 | - |
dc.identifier.url | https://journals.lww.com/jpharmacogenetics/Fulltext/2021/04000/A_pilot_study_to_investigate_the_utility_of_NAT2.3.aspx | - |
dc.contributor.alternativeName | Lee, Min Goo | - |
dc.contributor.affiliatedAuthor | 이민구 | - |
dc.citation.volume | 31 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 68 | - |
dc.citation.endPage | 73 | - |
dc.identifier.bibliographicCitation | PHARMACOGENETICS AND GENOMICS, Vol.31(3) : 68-73, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.